T1 mapping and ECV quantification by CMR represent a significant advancement in non-invasive myocardial tissue characterization, allowing for the detection of diffuse fibrosis and potentially guiding targeted heart failure therapies.
May enhance diffuse myocardial disease detection beyond LGE; leaves open prospective validation for HF therapy guidance.
Heart failure (HF) is a major and growing cause of morbidity and mortality. Despite initial successes, there have been few recent therapeutic advances. A better understanding of HF pathophysiology is needed with renewed focus on the myocardium itself. A new imaging technique is now available that holds promise. T1 mapping is a cardiovascular magnetic resonance (CMR) technique for non-invasive myocardial tissue characterization. T1 alters with disease. Pre-contrast (native) T1 changes with a number of processes such as fibrosis, edema and infiltrations. If a post contrast scan is also done, the extracellular volume fraction (ECV) can be measured, a direct measure of the interstitium and its reciprocal, the cell volume. This dichotomy is fundamental - and now measurable promising more targeted therapy and new insights into disease biology.
No takes yet. Share an insight, caveat, or question.
Maestrini et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: